Influenza A virus conserved epitope (IAV conserved epitope)

Influenza A virus conserved epitopes are stable antigenic regions within viral proteins that exhibit minimal variation across diverse strains and subtypes [1, 12]. These epitopes are primarily found in the hemagglutinin (HA) stalk (stem) region, the matrix protein 2 ectodomain (M2e), and internal proteins such as the nucleoprotein (NP) [3, 11]. While the HA head domain undergoes rapid antigenic drift, these conserved sites are critical for essential viral functions, including membrane fusion, ion channel activity, and RNA packaging [4, 9, 13]. Consequently, they are the primary focus for developing universal influenza vaccines and broadly neutralizing monoclonal antibodies (bnAbs) that aim to provide protection against both seasonal and pandemic strains [1, 14]. Therapeutic agents targeting these epitopes work through various mechanisms, such as blocking viral entry, inhibiting uncoating, or triggering immune effector functions like antibody-dependent cellular cytotoxicity (ADCC) [1, 11]. Despite their potential, challenges remain, including the immunodominance of variable regions and the low natural immunogenicity of certain conserved peptides [9, 14]. Furthermore, the phenomenon of Original Antigenic Sin (OAS) can complicate the immune response to these targets by favoring the recall of memory B cells against previously encountered, variable epitopes [8]. Successful targeting of these epitopes could lead to long-lasting, broad-spectrum immunity, reducing the need for annual vaccine updates [12].

Other names

Broadly protective influenza epitopesUniversal influenza vaccine targetsConserved IAV antigensConserved influenza epitopes

The mechanism of action involves the induction of broadly neutralizing antibodies that inhibit viral membrane fusion or attachment, as well as the activation of immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and T-cell mediated clearance of infected cells [1, 11, 14].